7 Feb 2008: In relation to the extraordinary general meeting of NorDiag ASA to be held on 8 February 2008 at 10:00 hours the following power of attorneys (POA) without specific instructions to vote on behalf of another shareholder that triggers disclosure has been received per 6 February 2008:

Name of proxy: Hans Hekland, chairman
Shares included under the POA:
- 3 155 981- owned by START-Fondet ASA
- 2 223 606 - owned by Biovekst AS
Percentage of shares held by principal:
- START-Fondet ASA 8,23 %
- Biovekst AS 5,8 %
Percentage of votes held by principal (excl POA):
- START-Fondet ASA 0 %
- Biovekst AS 0 %

Hans Hekland will in the general meeting also represent Sarsia Life Science Fund AS, which owns 6 210 661 shares (16,21 %) and Novel Diagnostics ASA which owns 3 845 660 shares (10,03 %). The POA`s only include authority to vote on behalf of a shareholder on the Extraordinary General Meeting of Nordiag ASA to be held on 8 February 2008, and expires on the conclusion of the General Meeting.

About NorDiag ASA:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. NorDiag has also launched a product for diagnostic of sexual transmitted infectious. In addition, the company has other applications for early diagnosis of cancer under development, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. www.nordiag.com.